Illumina (NASDAQ:ILMN) Shares Gap Down - Here's What Happened

Key Points

• Illumina shares plunged at the open, falling from a prior close of $290.06 to $255.77 and last trading near $251.67.
• Third-quarter adjusted earnings beat expectations, and management raised 2026 guidance on strong clinical sequencing demand and NovaSeq X adoption. However, revenue growth of 4.2% missed estimates amid China-related pressure, weaker research demand and pricing concerns.
• Analyst sentiment remains mixed: Illumina has a consensus “Hold” rating and an average price target of $234.41, while JPMorgan recently lowered its target to $300 from $320.

Illumina, Inc. (NASDAQ:ILMN - Get Free Report)'s stock price gapped down before the market opened on Friday. The stock had previously closed at $290.06, but opened at $255.77. Illumina shares last traded at $251.6740, with a volume of 591,460 shares traded.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina reported third-quarter adjusted earnings of $1.44 per share, above the $1.36 analyst consensus and up from $1.34 a year earlier. Illumina Q3 Earnings Beat Estimates
• Positive Sentiment: Management raised its 2026 guidance, citing strong clinical sequencing demand and continued adoption of the NovaSeq X platform. These trends support expectations for improved growth in clinical markets, even as research-related demand remains softer. ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical Growth
• Positive Sentiment: Longer term, Illumina remains positioned in expanding genomics markets, including clinical sequencing, population screening, metagenomics and precision medicine. 3 Promising Genomics Stocks to Add to Your Portfolio Now
• Neutral Sentiment: JPMorgan reduced its price target to $300 from $320, signaling somewhat lower near-term expectations while maintaining a target above recent trading levels. JPMorgan Adjusts Price Target on Illumina
• Negative Sentiment: Third-quarter revenue increased 4.2% year over year to approximately $1.13 billion but fell short of Wall Street expectations. Investors also reacted negatively to ongoing China revenue pressures, softer research demand and pricing pressure. Illumina Shares Tumble Despite Earnings Beat on China Woes

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ILMN shares. Barclays upped their target price on shares of Illumina from $160.00 to $200.00 and gave the company an "underweight" rating in a report on Wednesday, October 7th. Wall Street Zen raised Illumina from a "hold" rating to a "buy" rating in a report on Sunday, October 11th. Stifel Nicolaus boosted their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Stephens cut shares of Illumina from an "overweight" rating to an "equal weight" rating and set a $275.00 target price for the company. in a research note on Friday, October 23rd. Finally, JPMorgan Chase & Co. increased their price target on shares of Illumina from $220.00 to $230.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. Nine research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, Illumina has an average rating of "Hold" and a consensus price target of $234.41.

Illumina Price Performance

The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The company's 50 day moving average is $248.84 and its 200 day moving average is $175.73. The stock has a market cap of $35.94 billion, a price-to-earnings ratio of 44.50, a PEG ratio of 4.09 and a beta of 1.41.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the business posted $1.34 earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. Research analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the business's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the company's stock in a transaction on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the completion of the sale, the director directly owned 770,350 shares in the company, valued at $168,244,440. This trade represents a 13.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 2,061,235 shares of company stock worth $436,356,102. 2.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Illumina

Large investors have recently added to or reduced their stakes in the business. IPG Investment Advisors LLC acquired a new position in shares of Illumina in the 3rd quarter worth approximately $2,379,000. Signature Equity Partners LLC raised its position in shares of Illumina by 246.5% during the 3rd quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company's stock valued at $41,000 after acquiring an additional 106 shares in the last quarter. XML Financial LLC acquired a new stake in shares of Illumina during the 3rd quarter valued at approximately $320,000. Summit Wealth Group LLC Co. acquired a new stake in shares of Illumina during the 3rd quarter valued at approximately $270,000. Finally, Bank Julius Baer & Co. Ltd Zurich lifted its stake in Illumina by 1,901.0% during the third quarter. Bank Julius Baer & Co. Ltd Zurich now owns 6,203 shares of the life sciences company's stock worth $1,697,000 after purchasing an additional 5,893 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.